الرئيسية › السرطان النقيلي › ماساتشوستس › Boston
التجارب السريرية لـ السرطان النقيلي في Boston، MA
63 دراسات لـ السرطان النقيلي تبحث عن مشاركين في مواقع داخل وحول Boston (ضمن نطاق 30 ميلًا تقريبًا). افتح الدراسة لمعرفة من يمكنه المشاركة وكيفية التواصل مع فريق الدراسة.
النص الرسمي للدراسة (بالإنجليزية)
تبحث عن مشاركين لدراسة؟ أبرزها في أعلى الصفحة — $99 لمدة 30 يومًا →
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
جارٍ التسجيلالمرحلة 1/2
- Avenzo Therapeutics Recruiting Site, Boston
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
جارٍ التسجيلالمرحلة 2
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
جارٍ التسجيلالمرحلة 1
- Dana-Farber Cancer Institute, Boston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
جارٍ التسجيلالمرحلة 1
- Massachusetts General Hospital, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
جارٍ التسجيلالمرحلة 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
جارٍ التسجيلالمرحلة 1
- Dana Farber Cancer Institute, Boston
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Insitute, Boston
A Study of ASP3082 in Adults With Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
جارٍ التسجيلالمرحلة 2/3
- Dana-Farber Cancer Institute, Boston
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
جارٍ التسجيلالمرحلة 3
- Brigham and Women's Hospital (BWH), Boston
- Dana-Farber Cancer Institute (DFCI), Boston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
جارٍ التسجيلالمرحلة 1/2
- Dana Farber Cancer Institute., Boston
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
جارٍ التسجيلالمرحلة 1/2
- Mass General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
جارٍ التسجيلالمرحلة 1
- Mass General Cancer Center, Boston
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
جارٍ التسجيلالمرحلة 1
- Massachusetts General Hospital, Boston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
جارٍ التسجيلالمرحلة 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
جارٍ التسجيلالمرحلة 3
- Massachusetts General Hospital, Boston
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
جارٍ التسجيلالمرحلة 3
- Mass General Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- Dana Farber Cancer Institute, Boston
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
جارٍ التسجيلالمرحلة 1/2
- Massachusetts General Hospital - Main Campus, Boston
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
جارٍ التسجيلالمرحلة 1/2
- Brigham and Women's Hospital, Boston
- Dana Farber/Mass General Brigham Cancer Care, Inc, Boston
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
جارٍ التسجيلالمرحلة 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
جارٍ التسجيلالمرحلة 3
- Boston Medical Center, Boston
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
جارٍ التسجيلالمرحلة 1
- Dana-Farber Cancer Institute, Boston
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
جارٍ التسجيلالمرحلة 2
- Dana-Farber Cancer Institute, Boston
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
جارٍ التسجيلالمرحلة 1/2
- Avenzo Therapeutics Recruiting Site, Boston
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
جارٍ التسجيلالمرحلة 1/2
- Massachusetts General Hospital, Boston
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
جارٍ التسجيلالمرحلة 1
- Massachusetts General Hospital (MG), Boston
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
جارٍ التسجيلالمرحلة 1
- Dana-Farber Cancer Institute, Boston
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
جارٍ التسجيلالمرحلة 1
- Massachusetts General Hospital, Boston
FOG-001 in Locally Advanced or Metastatic Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
جارٍ التسجيلالمرحلة 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
جارٍ التسجيلالمرحلة 1
- Dana-Farber Cancer Institute, Boston
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
جارٍ التسجيلالمرحلة 1
- Dana-Farber Cancer Institute, Boston
A Study of PYX-201 in Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
جارٍ التسجيلالمرحلة 1
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
جارٍ التسجيلالمرحلة 1
- Exelixis Clinical Site #10, Boston
- Exelixis Clinical Site #11, Boston
A Study of LY4175408 in Participants With Advanced Cancer
جارٍ التسجيلالمرحلة 1
- Massachusetts General Hospital, Boston
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
جارٍ التسجيلالمرحلة 1
- Research Site, Boston
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
جارٍ التسجيلالمرحلة 1
- Research Site, Boston
- Research Site, Boston
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
جارٍ التسجيلالمرحلة 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
جارٍ التسجيلالمرحلة 1
- Massachusetts General Hospital, Boston
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
جارٍ التسجيلالمرحلة 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
جارٍ التسجيلالمرحلة 3
- Massachusetts General Hospital Cancer Center, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
جارٍ التسجيلالمرحلة 1/2
- Dana Farber Cancer Institute, Boston
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
جارٍ التسجيلالمرحلة 2
- I-Mab Site 1002, Boston
Remote Monitoring and Symptom Management Digital Application
جارٍ التسجيل
- Massachusetts General Hospital, Boston
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- Massachusetts General Hospital, Boston
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
جارٍ التسجيلالمرحلة 2/3
- Dana-Farber Cancer Institute, Boston
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
جارٍ التسجيلالمرحلة 3
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
جارٍ التسجيلالمرحلة 2/3
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
جارٍ التسجيلالمرحلة 2/3
- Massachusetts General Hospital, Boston
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
جارٍ التسجيلالمرحلة 1/2
- Dana-Farber Cancer Institute, Boston
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- Dana-Farber Cancer Institute, Boston
Venetoclax Basket Trial for High Risk Hematologic Malignancies
جارٍ التسجيلالمرحلة 1
- Dana-Farber Cancer Institute, Boston
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
جارٍ التسجيل
- Massachusetts General Hospital, Boston
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1
- Massachusetts General Hospital, Boston
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
جارٍ التسجيلالمرحلة 1
- Mass General Hospital, Boston
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
جارٍ التسجيلالمرحلة 1
- Massachusetts General Hospital, Boston
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
جارٍ التسجيلالمرحلة 3
- Dana-Farber Cancer Institute, Boston
IlluminOss Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pelvis Fractures
جارٍ التسجيلدراسة رصدية
- Massachusetts General Hospital, Boston
Comprehensive Outcomes for After Cancer Health
جارٍ التسجيلمرحباً بالمتطوعين الأصحاء
- Dana Farber Cancer Institute, Boston
تجارب السرطان النقيلي في مدن أخرى
- Houston, TX104 دراسات
- New York City, NY93 دراسات
- Nashville, TN70 دراسات
- Los Angeles, CA57 دراسات
- St. Louis, MO54 دراسات
- Arlington, VA53 دراسات
- Philadelphia, PA46 دراسات
- Chicago, IL45 دراسات
- San Antonio, TX44 دراسات
- Washington, DC43 دراسات
- Dallas, TX42 دراسات
- Seattle, WA39 دراسات
دراسات أخرى في Boston
- سرطان الثدي112 دراسات
- سرطان الرئة غير صغير الخلايا90 دراسات
- السرطان (جميع الأنواع)85 دراسات
- سرطان القولون والمستقيم63 دراسات
- سرطان الرئة62 دراسات
- سرطان المبيض61 دراسات
- سرطان البروستاتا59 دراسات
- الاكتئاب52 دراسات
- سرطان بطانة الرحم50 دراسات
- قصور القلب44 دراسات
- ابيضاض الدم النقوي الحاد44 دراسات
- سرطان البنكرياس43 دراسات
من ClinicalTrials.gov، البيانات مستخرجة في 06/10/2026. كل دراسة تحدد معايير أهليتها الخاصة؛ فريق الدراسة هو من يحدد من يمكنه المشاركة.